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Introduction:  There  is  a lack  of  knowledge  about  Health-Related  Quality  of  Life  (HRQL)  of Aboriginal  Aus-
tralians  with  self-reported  hepatitis  C  infection  in Western  Australia.  This  marginalised  group  of  people
is disproportionally  affected  by the  hepatitis  C  virus  (HCV)  for which  there  is  no  preventative  vaccine.
This  study  provides  data  that  help  understand  the long-term  consequences  of living with  HCV  infection
within  the Aboriginal  community.  It outlines  opportunities  for  nursing  interventions  for  hepatitis  care
that focus  on  supporting  mental  health  and  drug  and  alcohol  issues  within  this  population.
Methods:  We  surveyed  123  Aboriginal  people  living  with  HCV in  a community  setting.  Survey  data
included  demographics,  drug  use  history,  length  of  time  since  diagnosis,  changes  in lifestyle  since diag-
nosis, fatigue,  social  support,  alcohol  consumption,  and  physical  and  mental  health  measures.
Results:  Most  participants  reported  amphetamine  injecting  frequently  in  the  last  six  months  and  their
duration  of  injecting  drug  ranged  from  8 to  more  than 11  years.  Additionally,  half  of  the participants
were classified  as  high-risk  alcohol  users.  Overall  52% of participants  were  in  poor  physical  and  60%  of
participants  were  in  poor  mental  health.
Discussion:  This  survey  of  Aboriginal  people  with self-reported  hepatitis  C infection  indicates  substantial
problems  of  mental  and  physical  comorbidities  among  this  population.
Conclusion:  There  is a need  for the  development  of  HCV  community  clinics  in  Aboriginal  health  care
settings  with trained  Aboriginal  community  health  nurses  to reduce  problematic  alcohol  consumption,
assess  liver  health  and  subsequently  provide  HCV  treatment  in a culturally  appropriate  way.
©  2019  Australian  College  of  Nursing  Ltd.  Published  by  Elsevier  Ltd.  This  is an  open  access  article
under  the CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Summary of Relevance
Problem or Issue
Evidence suggests Aboriginal Australians are disproportionately affected by hepatitis C and this has a negative impact on physical and
mental quality of life. This study examined potential predictors of health-related quality of life (HRQL) in Aboriginal Australians with a
history of injecting drug use and currently living with hepatitis C.
What is Already Known
In this study we found that high levels of alcohol use; being more recently diagnosed with hepatitis C (between 1–4 years), using
methamphetamine and fatigue were the most common factors associated with poor mental and physical health among Aboriginal
Australians.
What this Paper Adds
Our findings support the integration of nursing interventions that can monitor and track HRQL over time for Aboriginal Australians
living with hepatitis C.
∗ Corresponding author.
E-mail addresses: a.rashidi@ecu.edu.au (A. Rashidi), P.Higgs@latrobe.edu.au (P. Higgs), S.Carruthers@curtin.edu.au (S. Carruthers).
https://doi.org/10.1016/j.colegn.2019.08.006
1322-7696/© 2019 Australian College of Nursing Ltd. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
A. Rashidi et al. / Collegian 27 (2020) 250–257 251
1. Introduction
Hepatitis C virus infection (HCV) is a significant public health
concern, affecting 170 million people worldwide (WHO, 2015).
Given the recent advances in hepatitis C treatment mean the
current number of people living with HCV has been reduced to
approximately 201,416 people (The Kirby Institute, 2018). The
Aboriginal Australian and Torres Strait Islander peoples (hereafter
Aboriginal Australians) comprise 3˜% of Australia’s population and
are over-represented in the prevalence of HCV as well as the inci-
dence of newly reported HCV cases (Graham, Harrod, Iversen, &
Hocking, 2016). Approximately 16,000 Aboriginal Australians were
infected with chronic HCV in 2008, representing 8.3% of the total
population infected with HCV in Australia (McNally & Latham,
2009). More recent data also indicate that in 2015, HCV rates among
Aboriginal Australians were four times higher than among non-
Aboriginals (The Kirby Institute, 2016). This can be explained by the
higher number of HCV case detections for Aboriginal Australians
who inject drugs and those who are in custodial settings (Lafferty,
Treloar, Chambers, Butler, & Guthrie, 2016). Recent research sug-
gests that the rate of newly diagnosed HCV among Aboriginal
Australians is 115 per 100,000 compared to the non-Aboriginal
rate of 40 per 100,000 (The Kirby Institute, 2016). Aboriginal
people experience disadvantage across a range of health and socio-
economic outcomes (Mitrou et al., 2014), which may  also mean
unequal access to health facilities to help manage health problems
associated with HCV.
It has been suggested that the impact of a HCV diagnosis alone
causes a reduction in HRQL (Groessl et al., 2008). HCV infection
may  be associated with impairment in health-related quality of
life (HRQL) (Strauss & Teixeira, 2006) even in the absence of liver
disease the impact of HCV seems to be most significant in mental
and physical functioning. For example, a considerable reduction in
HRQL was found in HCV-positive blood donors who  were unaware
of their status (Strauss, Porto-Ferreira, Almeida-Neto, & Teixeira,
2014). More recently, a treatment study with people newly infected
with HCV found significant associations between higher physical
HRQL and employment and lower physical HRQL and symptomatic
acute infection, while lower levels of mental HRQL were associated
with a history of injecting drugs (Doyle et al., 2016).
The burden of HCV can be exacerbated by the impact it has on
HRQL. HRQL is a multidimensional concept and refers to a patient’s
subjective assessment or perception of the impact of illness and/or
its treatment on physical, mental, and social well-being (Zautra &
Goodhart, 1979). Assessing HRQL and the associated factors are
important for identifying ways to improve individual health for
those living with HCV (Mahmoud, Shafik, & Attya, 2013), especially
in populations who have poor health outcomes, such as Aboriginal
people (Graham et al., 2016). Improving HRQL for individuals living
with chronic HCV can bring nurses to the front line in providing HCV
care, treatment, and support services (Lloyd et al., 2013). The evi-
dence suggests that nurses can provide guidance and indeed lead
to the management of HCV care and treatment (Ahern, Imperial, &
Lam, 2004).
Educating individuals with HCV infection has been shown
to improve HRQL through lifestyle changes initiated through
behavioural modification (Mahmoud et al., 2013). For exam-
ple, education on the monitoring of symptoms such as fatigue,
body pain, depression, and lack of ability to function effectively
(Mahmoud et al., 2013). Previous research has shown that individu-
als chronically infected with HCV respond to interventions focused
on increasing knowledge and this, in turn, improves functional sta-
tus and HRQL of individuals with chronic HCV (Sharif, Mohebbi,
Tabatabaee, Saberi-Firoozi, & Gholamzadeh, 2005).
While little attention has been given to the delivery of effective
HCV care in a culturally sensitive manner for Australian Aboriginal
people, it is well understood that the absence of appropriate cul-
tural respect can be a barrier to providing appropriate care (North
Coast Area Health Service, 2009). Cultural respect involves: “being
aware that Aboriginal culture differs from non-Aboriginal culture, and
that this culture may impact on the way that health and illness are
perceived, how Aboriginal people communicate, and which services
they are willing to access”  (North Coast Area Health Service, 2009,
31). Community health nurses are well placed to play a key role
in the provision of culturally sensitive HCV care. Despite previ-
ous research examining HRQL in people living with HCV, there
are no published studies specifically examining the impact of HCV
on HRQL among Aboriginal Australians. To date, considerations of
HRQL have not been a focus in the development of HCV intervention
strategies for Aboriginal Australians with chronic HCV.
1.1. Aim
This study aimed to examine what factors predict HRQL among
Aboriginal people with a history of injecting drugs and who  are
living with chronic HCV. Knowing this will inform strategies for
monitoring the physical and mental health of Aboriginal drug injec-
tors over time.
2. Methods
2.1. Setting
Participants were recruited through multiple sites across the
Perth metropolitan area. These sites include the peer-based West-
ern Australian Substance Users Association (WASUA) in Perth and
Bunbury; Hepatitis WA;  WA  AIDS Council (WAAC) Needle Syringe
Exchange Program (NSEP) fixed site; and WAAC NSEP mobile
van services, operating in eight locations in the metropolitan
area (Rockingham, Mirrabooka, Joondalup, Midland, Forrestfield,
Armadale, Fremantle and Gosnells).
2.2. Sampling
The level of HRQL was  used to determine the sample size; this
study used the higher proportion of 50%, that is, it was assumed
that 50% of the sample would have poor HRQL and 50% would not
have poor HRQL. By an acceptable sampling error of 9% at a 95%
level of confidence (de Vaus, 1991) and employing the following
formula (Kirkwood, 2000), the overall sample is:
n (1 − n)
e2
= 50 (100 − 50)
4.52
= 123
where n is the proportion and e the required size of standard error.
Sampling error is two  standard errors.
2.3. Participants
Current drug injectors who  self-identified as Aboriginal and/or
Torres Strait Islander and living with HCV were invited to partic-
ipate in a cross-sectional survey. The eligibility criteria for study
participants included: being 18 or more years of age; current inject-
ing drug use; self-reported as having received an HCV diagnosis by
a health care professional more than six months prior to interview;
no previous experience of HCV treatment; and currently living in
Western Australia. The main reason for choosing those with no
experience of HCV treatment was  to better understand how cur-
rently living with HCV can impact on both mental and physical
HRQL.
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2.4. Data collection
The survey was used to collect information from the 123 par-
ticipants. Recruitment was undertaken through the distribution
of study posters and information sheets at the venues previously
described, and potential participants contacted the researcher
directly by phone where eligibility was determined and a mutu-
ally agreeable time was arranged to complete the questionnaire.
Consent was obtained, and the questionnaires were completed in a
private room at the recruitment site inside or in the WAAC mobile
van, or next to the mobile van wherever they felt comfortable and
safe reading and responding to the questions. Participants were rec-
ompensed for their time and expertise with a supermarket voucher
valued at AU $20 on completion of the questionnaire.
2.5. Measures
2.5.1. Independent variables
The survey was adapted from validated survey instruments and
included: socio-demographic and drug-history (Loxley, Carruthers,
& Bevan, 1995), changes in lifestyle since HCV diagnosis (Horwitz,
Brener, & Treloar, 2012), length of time since diagnosis (McNally,
Sievert, & Pitts, 2006), fatigue (Fábregasa et al., 2013) and social sup-
port (Zimet, Dahlem, Zimet, & Farley, 1988). Alcohol consumption
was measured using the AUDIT-C scale (Bush, Kivlaham, Mcdonell,
Fihn, & Bradley, 1998).
The first section (socio-demographic and drug history) con-
tained questions about age, gender, accommodation, level of
education, marital status, history of incarceration, residency status,
drug use duration, frequency of injection and drug preference. Age
in years was converted into a binary variable using the median score
as the cut off (Tolmie, Muijs, & McAteer, 2011), <38 years old and
≥38. All participants selected heroin or amphetamine as their pre-
ferred drug and the drug that they had injected recently, also they
reported injecting drugs for “8–10” years or “more than 11 years”
and reported injecting drugs either “once a day” or “more than once
a day”, therefore the duration of injecting and frequency of injection
was re-categorised accordingly. Alcohol consumption was assessed
with 3 items (the first three questions of the full AUDIT). Alcohol
consumption scores greater than 3, and 4 indicate high-risk con-
sumption among women and men, respectively (Bush et al., 1998).
These variables are considered as covariates.
The second section on changes in lifestyle since HCV diagnosis
asked participants whether changes in their lifestyle had occurred
since HCV diagnosis. This section contained 5 items; changes in diet,
reduced or removal of alcohol, increased physical exercise, HCV
monitoring, and any use of complementary medicines. Lifestyle
changes scores were coded as a dichotomous no or yes. The items
were summed together to form lifestyle changes scales; a higher
score indicated greater behavioural changes. This section also asked
the participants the length of time since their HCV diagnosis. The
third section, on family/friend support, asked whether participants
had support if they chose to undergo HCV treatment, which was
measured by 8 items. For analysing social support, scores were
grouped as “disagree” (grouping together the first three responses)
and “agree” (the last two  answers); the response “neutral” was
included in the first group as it indicated that the subject did not
necessarily agree (Alavi et al., 2015). Disagree and agree were re-
categorised into “No” and “Yes”. Fatigue was measured through the
Brief Fatigue Inventory (BFI) consisting of 10 items. Fatigues were
categorised in mild (0–3 points), moderate (4–6 points), or severe
fatigue (7–10 points) (Fábregasa et al., 2013).
2.5.2. Dependent variables
Mental and physical HRQL were measured using a 36-Item Short
Form Health Survey (SF-36), the most common generic instru-
ment for measuring HRQL and one used in previous HCV research
(Ferreiraa, Almeida-Netoa, Teixeirab, & Strauss, 2015). This instru-
ment is based on items related to physical and mental health status
and can be applied to any disease and even to healthy subjects
across eight domains (Ferreiraa et al., 2015). The SF36 is a validated
measurement (Ferreiraa et al., 2015), which created a physical com-
ponent summary (PCS) and a mental component summary (MCS).
The PCS was  used to assess physical health status, consisting of four
domains; physical functioning, physical role, bodily pain, and gen-
eral health perception. MCS  consisted of vitality, social functioning,
emotional role, and mental health scales. PCS and MCS  score ranged
from 0 (zero), corresponding to the worst health condition possible,
to 100 (one hundred), corresponding to the best possible HRQL. PCS
and MCS  were categorised by the sample’s median, poor PCS and
MCS were defined as having a score lower than median value, this
scoring system was  adopted from the previous study (Marcuello
et al., 2012).
2.6. Data analysis
Data from the questionnaires were coded and entered into SPSS
(version 22; IBM, Chicago, USA) and cleaned prior to data analy-
sis. Descriptive analysis was  conducted to describe the background
characteristics on all variables (predictors and outcomes) in the
study, and percentage distributions for all variables were calculated
to describe the full sample of participants. Bivariate analyses were
conducted on all variables. Multivariate analyses (logistic regres-
sion) were conducted when there was more than one variable
associated with the dependent variable p < 0.10 in bivariate analy-
ses. All covariates were entered into the models. The variables with
p < 0.10 in bivariate analyses were included as candidate measures
in the multivariate model. In the multivariate analysis, p < 0.05 was
considered for the retention of variables. The probability level of
95% was applied in all statistical tests.
2.7. Ethical considerations
Ethical approval for the study was granted by the Curtin Uni-
versity and Fremantle Hospital Human Research Ethics Committee
(Reference Number: 12/198 and HR 77/2012). To ensure that par-
ticipants were able to provide informed consent, the objectives,
procedures, and implications of the study were explained clearly
to interested potential participants. An information sheet and con-
sent form were offered, and participants were informed that they
were free to withdraw at any time. The primary researcher (AR)
offered a follow-up interview, as support to participants who emo-
tionally affected by speaking about their experience. Referral made
to Hepatitis WA,  where provides a support service for people with
hepatitis C. However, none of the participants expressed their inter-
est in the follow-up interview.
3. Results
3.1. General characteristics of the study sample
Of the 123 participants who completed the survey, over three-
quarters were male (77.2%) and the median age of participants was
38 years. Most participants had a stable home and lived alone. The
majority (83.7%) of participants had left school at or prior to com-
pleting Year 11. Just over half of all participants (55.3%) lived in
a metropolitan area. Most participants (81.3%) described them-
selves as unemployed and derived their main source of income
from government benefits. Heroin or methamphetamine was the
only commonly injected drugs reported by participants in the six
months prior to the interview. Almost 59% of participants had
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Table  1
Socio-demographic data of survey participants.
Characteristics n %
Gender
Male 95 77.2
Female 28 22.8
Median age (range) 38(24–60)
Accommodation
Non-homeless 86 69.9
homeless 37 30.1
Education
<year 11 103 83.7
≥year 11 20 16.3
Employment
Full  or part time 23 18.7
Government benefits 100 81.3
Residency status
Metropolitan 68 55.3
Non-metropolitan 55 44.7
Imprisonment
Yes,  not in the last 6 months 79 64.2
Yes,  in the last 6 months 44 35.8
Recent injecting drug use
Heroin 72 58.5
Methamphetamine 51 41.5
Drug duration
8–10 years 51 41.5
More than 11 years 72 58.5
Frequency of injection
Once a day 40 32.5
More than once a day 83 67.5
Alcohol consumption
Low risk 49 39.8
High risk 74 60.2
Time since diagnosed
5–10 48 39
1–4  75 61
Social support
Yes 65 52.8
No  58 47.2
Positive Lifestyle change
Yes 68 55.3
No  55 44.7
Fatigue
Moderate 63 51.2
Severe 60 48.7
SF  36 domains
Mental component score, median (range) 52(52.5–40)
Not poor physical health 56 45.5
Poor physical health 67 54.5
SF  36 domains
Physical component score, median (range) 51 (52.5–40)
Not poor physical health 59 48
Poor physical health 64 52
injected amphetamine, most in the last six months. More than two-
thirds of participants (67.5%) reported injecting more than once a
day. The duration of injecting drug use for the participants ranged
from 8 to more than 11 years. No participants reported injecting
for less than 8 years. One-third of the participants reported inject-
ing for 8–10 years. Nearly half of the participants were classified as
high-risk alcohol users using AUDIT-C ranking, and 61% of partici-
pants had been diagnosed with HCV between 1–4 years previously.
Almost 53% of the participants reported a supportive network of
either family or friends. Less than half of participants reported no
positive lifestyle changes since diagnosis with HCV. Further char-
acteristics of the sample are presented in Table 1.
3.2. Factors associated with mental health status
Unadjusted analyses of factors associated with poor mental
health are shown in Table 2. In adjusted analysis, unemployment
(AOR: 4.49 95% CI: 1.39,14.48), high risk alcohol use (AOR: 8.01,95%
CI: 2.37,27), being diagnosed with HCV infection between 1–4 years
(AOR: 4.2,95% CI: 1.3,14.14), methamphetamine use (AOR: 4.3,95%
CI: 1.3,14.07) and fatigue (AOR: 8.35,95% CI: 2.47,28.22) were asso-
ciated with poor mental health status.
3.3. Factors associated with physical health status
Unadjusted analyses of factors associated with the poor physi-
cal role are shown in Table 3. In adjusted analysis older age (AOR:
3.81, 95% CI: 1.22, 11.94), high risk alcohol use (AOR: 8.55, 95%
CI: 2.49,29.35), being diagnosed with HCV infection between 1–4
years (AOR: 4.5,95% CI: 1.39,14.59) methamphetamine use (AOR:
3.52,95% CI: 1.1,1.18) and fatigue (AOR: 8.13,95% CI: 2.54,26.03)
were associated with poor physical status.
4. Discussion
This cross-sectional study was conducted to determine the mea-
sures required to improve HRQL of Aboriginal Australians with
a history of injecting drugs and with chronic HCV. This study
describes the demographic, physical, and mental health character-
istics of Western Australian Aboriginal individuals who  were HCV
treatment naïve. To our knowledge, very few Australian studies
have assessed both the mental and physical health status of this
population within a community setting. This is the first study to
assess HRQL in Aboriginal people who inject drugs who report being
diagnosed with HCV using the SF36 and fatigue instruments. The
data shows HRQL impairments for participants, especially in the
physical and mental components of the instruments. The impact of
an HCV diagnosis coupled with patterns of injecting drug use and
other chronic conditions may  aggravate the quality of life among
HCV treatment naïve patients.
In this study, over half of the participants were classified as hav-
ing poor physical (52%) and mental health (60%) status using the
SF-36 scale. We found that HRQL scores were significantly lower
than previously recorded in recently treated chronic HCV patients
(Younossi et al., 2017). This finding indicates that Aboriginal people
who inject drugs have a reduced quality of life in physical, men-
tal and, general health domains. This support the development of
nurse-led interventions which target improving HRQL by focusing
on physical HCV symptoms and addressing psychological needs in
a culturally client centred sensitive manner.
The multivariate analysis showed an independent association
between poor physical and mental HRQL and high-risk alcohol
use, unemployment, older age, being diagnosed with HCV infection
between 1–4 years previously, methamphetamine use and fatigue.
It has been well established that HCV infection impacts on disease
progression and other health outcomes and negatively affects phys-
ical functioning and mental health of individuals with chronic HCV
(Gao, Gao, Li, Shang, & Yu, 2013). Additionally, in this study, alco-
hol consumption did not change significantly after HCV diagnosis
and may  indicate participants in this study were unaware of the
impact of alcohol consumption on their health. Given its relative
affordability as well as greater social acceptability, alcohol use was
common. High levels of alcohol consumption among participants in
this study was not surprising and highlights the negative impact of
alcohol use on HRQL among people living with HCV (Costenbader,
Zule, & Coomes, 2007).
More than one-third of participants in our study showed severe
fatigue according to BFI, similar to fatigue rates reported among
HCV patients in another study (Basseri et al., 2010). An earlier study
among people with HCV-HIV co-infection identified fatigue was
associated with impairment in physical and mental HRQL domains,
and was  a strong predictor of reducing HRQL (Fábregasa et al.,
2013). Fatigue among participants in our study could be associ-
ated with depression, alcohol consumption, and other drug use. An
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Table 2
Unadjusted and adjusted analyses of factors associated with mental health status.
Characteristics Not poor Mental HRQL Poor Mental HRQ OR (95%CI) p-value AOR (95%CI) p-value
Gender
Male 37(38.9) 58(61.1)
Female 19(67.9) 9(32.1) 0.3(0.12,0.73 p < 0.001
Age
<38  years 39 (72.2) 15 (27.8)
≥38  years 17 (24.6) 52(75.4) 7.95 (3.54,17.85) p < 0.001
Accommodation
Non-homeless 44(51.2) 42(48.8)
homeless 12 (32.4) 25(67.6) 2.18 (0.97,4.89) p = 0.05
Education
<year 11 42(40.8) 61(59.2)
≥year 11 16 (80) 6(30) 0.29 (0.1,0.83) p = 0.01
Employment
Full  or part time 51(51) 49(49)
Government 5(21.7) 18 (78.3) 3.74(1.29,10.87) p = 0.01 4.49(1.39,14.48) p < 0.01
benefits
Residency status
Metropolitan 43(63.2) 25(36.8)
Non-metropolitan 13(23.6) 42(76.4) 5.55(2.51,12.89) p < 0.001
Imprisonment
Not  within the last 6 months 46 (58.2) 33(41.8)
In  the last 6 months 10(22.7) 34(77.3) 4.73 (2.05,10.92) p < 0.001
Recent injecting drug use
Heroin 43 (59.7) 29(40.3)
Methamphetamine 13 (25.5) 38(74.5) 4.33 (1.97,9.51) p < 0.001 4.3(1.3,14.07) p < 0.01
Drug  duration
8–10 years 18(35.3) 33(64.7)
More than 11 years 38(52.8) 34(47.2) 0.48 (0.23,1.02) p = 0.05
Frequency of injection
Once a day 13 (32.5) 27(67.5)
More than once a day 43 (51.8) 40(48.2) 0.44(0.2,0.98) p = 0.04
Alcohol consumption
Low risk 41 (83.7) 8 (16.3)
High risk 15 (20.3) 59 (79.7) 20.15(7.82,51.92) p < 0.001 8.01(2.37,27) p < 0.001
Year  since diagnosed
5–10 37(58.7) 26(41.3)
1–4 19(31.7) 41(68.3) 3.07(1.46,6.43) p < 0.001 4.2(1.3,14.14) p = 0.01
Social  support
Yes 36(55.4) 29(44.6)
No 20 (34.5) 38(65.5) 2.35 (1.13,4.89) p = 0.02
Fatigue
Moderate 37 (58.7) 26(41.3)
Severe 19(31.7) 41 (68.3) 3.071(1.46,6.43) p < 0.001 8.35(2.47,28.22) p < 0.001
Positive  Lifestyle change
Yes 44(64.7) 24(35.3)
No 12(21.8) 43 (78.2) 6.56 (2.92,14.77) p < 0.001
effective nursing intervention to reduce the burden of fatigue is
required. However, this cross-sectional study did not allow us to
identify the causality between these factors and depression, hence
further a prospective cohort study with a large, nationally repre-
sentative sample is required to verify and enrich the results of the
present study.
Being infected with HCV was associated with lower scores
in physical and mental HRQL domains, which was expected and
similar to a previous study (Younossi et al., 2015). Age also sig-
nificantly influenced the HRQL physical domain. Older age was
independently associated with diminishing effects upon quality of
life (McDonald et al., 2013).Using methamphetamine had signifi-
cant associations with poor physical and mental HRQL (Gonzales
et al., 2009). This suggests that certain illicit drugs use may  have
a greater impact on HRQL and may  play a more central role in
decreasing HRQL physically and mentally. The presence of illicit
drug use could be associated with changes in mental and physical
functions of individuals. This is consistent with previous research
showing methamphetamine was associated with poorer mental
and physical quality of life (Gonzales et al., 2009). Apart from med-
ical treatment, nurses working within Aboriginal cultural contexts
can provide supportive links to drug and alcohol counsellors and
other services to meet an individual’s needs.
Limited understanding of HCV symptoms, including lack of
symptoms, may  deter Aboriginal Australians from engaging in
HCV treatment (Brener et al., 2016). Experiences of stigma and
discrimination related to HCV, injecting drug use, and particu-
larly Aboriginality can all be intensified for Aboriginal Australians
(Brener et al., 2016) when compared to others living with HCV.
Effective HCV pre and post-test discussions, including HCV diag-
nosis by nurses who can provide the necessary information about
managing HCV (including referral for treatment) could help reduce
these barriers to HCV care. As many Aboriginal Australians report
more pressing health and social priorities (McNally & Latham,
2009), community nurses may  be well placed to manage health
problems associated with HCV. This includes education on the
asymptomatic nature of HCV and the importance of lifestyle mod-
ifications including reducing alcohol use, maintaining a healthy
weight and ongoing medical visits to prevent or delay liver
damage (Ingrid Hickman et al., 2002). Such information and edu-
cation particularly when they are provided by Aboriginal health
workers can ensure culturally appropriate HCV care. Analysis
of intervention studies should be undertaken to create HRQL
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Table  3
Unadjusted and adjusted analyses of factors associated with physical health status.
Characteristics Not poor Physical HRQL Poor Physical HRQL OR (95%CI) p-value AOR (95%CI) p-value
Gender
Male 40(42.1) 55(57.9)
Female 19(67.9) 9(32.1) 0.34 (0.14,0.84) p = 0.01
Age
<38  years 40 (74.1) 14 (25.9)
≥38 years 19 (27.5) 50(72.5) 7.51 (3.35,16.83) p < 0.001 3.81(1.22,11.94) p = 0.02
Accommodation
Non-homeless 46(53.5) 40(46.5)
homeless 13 (35.1) 24(64.9) 2.12 (0.95,4.71) p = 0.06
Education
<year 11 45(43.7) 58(56.3)
≥year 11 14 (70) 6(30) 0.33 (0.11,0.93) p = 0.03
Employment
Full  or part time 53(53) 47(47)
Government 6(26.1) 17 (73.9) 3.19 (1.16,8.77) p = 0.02
benefits
Residency status
Metropolitan 42(61.8) 26(38.2)
Non-metropolitan 17(30.9) 38(69.1) 3.61(1.7,7.66)
Imprisonment
Yes,  not in the last
6  months 47 (59.5) 32(40.5)
Yes,  in the last 6 months 12(27.3) 32(72.7) 3.91 (1.75,8.72) p < 0.001
Recent injecting drug use
Heroin 44 (61.1) 28(38.9)
Methamphetamine 15 (29.4) 36(70.6) 3.77 (1.75,8.11) p < 0.001 3.52(1.1,11.18) p = 0.03
Drug  duration
8–10 years 19(37.3) 32(62.7)
More than 11 years 40(55.6) 32(44.4) 0.47 (0.22,0.98) p = 0.04
Frequency of injection
Once a day 14 (35) 26(65)
More than once a day 45(54.2) 38(45.8) 0.45(0.2,0.99) p = 0.04
Alcohol consumption
Low risk 42 (85.7) 7 (14.3)
High risk 17 (23) 57 (77) 20.11(7.65,52.87) p < 0.001 8.55(2.49,29.35) p < 0.001
Year  since diagnosed
5–10 39(61.9) 24(38.1)
1–4  20(33.3) 40(66.7) 3.2 (1.55,6.8) p < 0.001 4.5(1.39,14.59) p = 0.01
Social  support
Yes 36(55.4) 29(44.6)
No  23(39.7) 35(60.3) 1.88 (0.92,3.87) p = 0.08
Positive Lifestyle change
Yes 43(63.2) 25(36.8)
No  16(29.1) 39 (70.9) 4.19 (1.95,8.98) p < 0.001
Fatigue
Moderate 52(34.1) 19(26.8)
Severe 7(13.5) 45(86.5) 17.59(6.77,45.67) p < 0.001 8.13(2.54,26.03) p < 0.001
database in order to develop HCV management program and to
measure ongoing Aboriginal HRQL in the near future. Also, pro-
moting community-based self-management and care programs
for HCV may  support and develop better physical and mental
health.
5. Limitations
There are limitations to this study, which must be noted. Firstly,
there was no serological testing to confirm self-reported HCV status
as participants were primarily recruited from non-clinical settings.
However, previous studies, particularly Australian studies, indicate
good levels of validity and reliability for self-reported HCV data
(O’Keefe, Aitken, Higgs, & Dietze, 2013). To minimise this bias, we
specified receiving an HCV diagnosis by a health care professional
as an inclusion criterion for this study and this likely improved the
self-reporting accuracy. Self-reporting is also susceptible to social
desirability bias. However, SF-36 is a validated and reliable instru-
ment which involves a mixture of both positively and negatively
worded helping to minimise this bias (Doyle et al., 2016). Also, the
survey was administered when the participant had no experience
of HCV treatment meaning their experience living with HCV was
still memorable. Thirdly, selection bias may  have occurred in the
study sample, as the sample was  based on convenience, not a ran-
dom sample. Recruiting primarily from community-based needle
syringe programs may  have led to a potential bias towards partic-
ipants who  had better access to health care services. To minimise
this and to increase the geographical diversity in the sample, data
was collected at three different NSP sites including Bunbury and a
mobile service visiting eight suburbs, where almost half the par-
ticipants identified themselves as a non-metropolitan resident at
the time of being interviewed. The study sample was not diverse in
terms of age and duration of injection, for example, a small minor-
ity of study participants (17%) were aged below 30 years, and all
study participants had injected for more than eight years, which is
not representative of the entire population of HCV-infected Aborig-
inal people who inject drugs in Perth. Therefore, the findings of this
study are not generalisable to other Aboriginal people in Australia.
Another limitation was the cross-sectional study design, which it
is not possible to make any causal inference about the relationship
between the predictors and HRQL.
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6. Conclusion
In conclusion, these findings provide new insights into the qual-
ity of life of Aboriginal Australians living with chronic HCV. It shows
the impact of HCV on mental and physical health status in Aborigi-
nal people who inject drugs with chronic HCV. This study confirms a
need for nursing interventions which monitor and track HRQL over
time among Aboriginal people who inject drugs with chronic HCV.
Even with the advent of interferon-free all-oral HCV treatments,
psychosocial and socioeconomic factors will likely continue to be a
significant barrier to treatment uptake for people who inject drugs
(Higgs, Wright, & Hellard, 2016). We  argue that there is a need for
nursing led and focused HCV interventions which could improve
the physical and mental HRQL for Aboriginal Australians. Engage-
ment in HCV diagnosis, treatment, and care may  also result in better
self-management and care of the long-term consequences of HCV
infection within the Aboriginal community. Data from our study
suggest attention to preventive care and strategies to reduce exces-
sive alcohol consumption are also required. Ultimately this could
result in the establishment of HCV community clinics in Aborigi-
nal health care settings with trained Aboriginal community health
nurses who can provide support, encourage drug users to assess
their liver health and subsequently undertake HCV treatment in a
culturally appropriate way.
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